Sofinnova Investments' Jakob Dupont on the private markets in biotech
Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND. He thinks the IPO market will be available for advanced companies in 2024.
Also look for unique social pages for BiotechTV U.
10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.
Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.